highly significantp < 0.0001
➣ Subgrouping of vaccinated cases according to used vaccine revealed three groups: Group 1: Pts received viral vector-based vaccines with adverse events Group 2: Pts received mRNA-based vaccines with adverse events Group 3: Pts received inactivated virus vaccines with adverse events Comparing each two groups as regards adverse events done and revealed the following results Comparing group 1 to group 2 Viral vector-based vaccine group (group 1) showed highly significant increase in cases of thrombotic thrombocytopenic purpura/cerebral venous thrombosis/pulmonary embolism with p < 0.0001 In the same context, group 1 had statistically significant increase in cases of DIC ( P = 0.0316), GBS ( P = 0.0036) and ATM ( P = 0.0089).